Literature DB >> 4646774

The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects.

W Y Au, L G Dring, D G Grahame-Smith, P Isaac, R T Williams.   

Abstract

1. The fate of orally administered (14)C-labelled l-alpha-methyldopa has been examined in three normal men and in eight hypertensive patients who responded to the drug and three who did not. 2. The output of (14)C in the urine in 2 days and in the faeces in 4 days was not very different in any of the subjects. The normals excreted about 40% of the dose in the urine and 60% in the faeces, the responders 52% (range 35-60%) and 45% and the non-responders 42% and 41%. Most of the urinary (14)C radioactivity was eliminated in 24h after dosing. 3. The main metabolite in the urine was free and conjugated alpha-methyldopa (normal men, 23%; responders, 37%; non-responders, 25% of the dose). Free and conjugated 3-O-methyl-alpha-methyldopa was about 4% in all subjects, total amines (alpha-methyldopamine and 3-O-methyl-alpha-methyldopamine) about 6% and ketones (mainly 3,4-dihydroxyphenylacetone) about 3%. 4. The output of alpha-methyldopamine (2-4% of dose), 3-O-methyl-alpha-methyldopamine (0.3%) and 3,4-dihydroxyphenylacetone (3-5%) was similar in the one normal and two responders examined. 5. The faecal (14)C in all subjects was unchanged l-alpha-methyldopa. 6. In general, the amounts of the metabolites in the urine in normal men and in responding and non-responding patients were quantitatively similar, except in one non-responding patient who converted nearly two-thirds of the absorbed drug into amines and ketones. There appeared to be no correlation between metabolites in the urine and response or lack of response to the drug. 7. In two normal subjects 70-80% of d-alpha-methyldopa was excreted unchanged in the faeces. Of the absorbed compound most (9-14% of the dose) was excreted as the free and conjugated drug together with a small amount (1-2%) of 3-O-methyl-alpha-methyldopa. No amines and only traces of ketone were excreted.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4646774      PMCID: PMC1174035          DOI: 10.1042/bj1290001

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS.

Authors:  R P BUHS; J L BECK; O C SPETH; J L SMITH; N R TRENNER; P J CANNON; J H LARAGH
Journal:  J Pharmacol Exp Ther       Date:  1964-02       Impact factor: 4.030

2.  STUDIES ON THE METABOLISM AND MECHANISM OF ACTION OF METHYLDOPA.

Authors:  A SJOERDSMA; A VENDSALU; K ENGELMAN
Journal:  Circulation       Date:  1963-10       Impact factor: 29.690

3.  RESTORATION OF TYRAMINE PRESSOR RESPONSES IN RESERPINE-TREATED ANIMALS BY METHYLDOPA AND ITS AMINE METABOLITES.

Authors:  W A PETTINGER; S SPECTOR; D HORWITZ; A SJOERDSMA
Journal:  Proc Soc Exp Biol Med       Date:  1965-04

4.  Distribution and metabolism of methylopa in the rat.

Authors:  C C PORTER; D C TITUS
Journal:  J Pharmacol Exp Ther       Date:  1963-01       Impact factor: 4.030

5.  On the use of strong exchange resins for determinations of small amounts of catechol amines.

Authors:  J HAGGENDAL
Journal:  Scand J Clin Lab Invest       Date:  1962       Impact factor: 1.713

6.  The separation and identification of some sympathomimetic amines by paper partition chromatography.

Authors:  A WICKSTROM; B SALVESEN
Journal:  J Pharm Pharmacol       Date:  1952-09       Impact factor: 3.765

7.  Specificity of the transport system for neutral amino acids in the hamster intestine.

Authors:  E C LIN; H HAGIHIRA; T H WILSON
Journal:  Am J Physiol       Date:  1962-05

8.  A correlation between the hypotensive action of methyldopa and its depression of peripheral sympathetic function.

Authors:  G K Salmon; J D Ireson
Journal:  Arch Int Pharmacodyn Ther       Date:  1970-01

9.  Combined clinical and metabolic study of the effects of alpha-methyldopa on hypertensive patients.

Authors:  L F Prescott; R P Buhs; J O Beattie; O C Speth; N R Trenner; L Lasagna
Journal:  Circulation       Date:  1966-08       Impact factor: 29.690

10.  The metabolic fate of amphetamine in man and other species.

Authors:  L G Dring; R L Smith; R T Williams
Journal:  Biochem J       Date:  1970-02       Impact factor: 3.857

View more
  16 in total

Review 1.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

2.  Pharmacokinetics of methyldopa in healthy man.

Authors:  O Stenbaek; E Myhre; H E Rugstad; E Arnold; T Hansen
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

3.  Influence of the decarboxylase inhibitor benserazide on the antihypertensive effect and metabolism of alpha-methyldopa in patients with essential hypertension.

Authors:  G Planz; H W Gierlichs; A Hawlina; R Planz; W Stephany; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

4.  Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers.

Authors:  K Róna; K Ary; G Renczes; B Gachályi; G Y Grézal; S Drabant; I Klebovich
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

Review 5.  Antihypertensive pharmacology.

Authors:  J G Gerber; C R Freed; A S Nies
Journal:  West J Med       Date:  1980-05

6.  Turnover of myelin and other structural proteins in the developing rat brain.

Authors:  M I Sabri; A H Bone; A N Davison
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

7.  Plasma concentration of alpha-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester.

Authors:  J A Saavedra; J L Reid; W Jordan; M D Rawlins; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1975-08-14       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of methyldopa.

Authors:  E Myhre; H E Rugstad; T Hansen
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

9.  A study of the transfer of alpha-methyldopa to the human foetus and newborn infant.

Authors:  H M Jones; A J Cummings
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

10.  The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment.

Authors:  A G Renwick; V Higgins; K Powers; C L Smith; C F George
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.